Reply  by Mehta, Rohit et al.
D
a
W
M
a
a
c
M
m
I
r
p
t
(
c
s
w
o
C
i
a
F
i
o
a
C
p
B
I
m
d
d
t
i
i
d
o
i
L
LG
L
P
Journal of the American College of Cardiology Vol. 52, No. 23, 2008
© 2008 by the American College of Cardiology Foundation ISSN 0735-1097/08/$34.00
Published by Elsevier Inc.CORRESPONDENCELetters to the Editor
d
p
r
o
t
p
s
t
o
r
i
*
S
C
*
C
A
B
B
E
R
1
2
R
D
i
(
n
d
M
b
d
i
q
b
o
d
q
p
o
t
ievice Interactions
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e read with much interest the Research Correspondence by
ehta et al. (1) of 2 cases of device interactions in patients with
dvanced cardiomyopathy. We experienced the same problem with
patient equipped with a St. Jude Medical (SJM) implantable
ardioverter-defibrillator (Atlas II  HF, model V-367, St. Jude
edical, Sunnyvale, California) who was implanted with a Heart-
ate II left ventricular assist device (LVAD) (Thoratec Heartmate
I, Thoratec, Pleasanton, California). Similar to the 2 cases
eported by the group of Mehta et al. (1), our case demonstrated no
ossible telemetry after the implantation of the LVAD pump, and
he replacement of the implantable cardioverter-defibrillator
ICD) was the only clinical solution. Mehta et al. (1) partially
larified the nature of the interaction. We also found that it was
pecifically produced by the Heartmate II pulse-width modulator,
hich operates at a constant frequency of 7.2 kHz. However, in
ur case, the patient was implanted with a new generation of SJM
RT-D (which uses an operating frequency of 64 kHz). Accord-
ng to the explanation given in the correspondence from Mehta et
l. (1), no interaction would have been expected. In fact, the
ederal Communications Commission who regulates the operat-
ng frequencies of all implantable devices has mandated device
perating in UHF bands to use a “listen-before-talking” (LBT)
ccessing protocol for safety reasons (2). All ICDs, even the last
urrent and Promote generation from SJM, use an LBT assessing
rotocol operating at a frequency of 8 kHz (communication from SJM
elgium, St. Jude Medical, Zaventem, Belgium, April 2008) (Table 1).
nteractions could thus occur either between the pulse-width
odulator and the LBT protocol (newest generation) and/or the
ata transmission per se (oldest generation). This was clearly
emonstrated by clinical tests that we performed with demonstra-
ion devices: the initial interrogation of all SJM ICDs is always
mpossible if the distance between the ICD and the LVAD pump
s shorter than 6 inches. However, the communication to the
evice is possible close to the Heartmate for the newest generation
f SJM ICDs (LBT: 8 kHz; operating frequency: 64 kHz) if the
nitial recognition of the ICD is established far away from the
VAD pump. By contrast, with the oldest generation of SJM
BT, Operating, and Wireless Frequencies Used by Differentenerations of SJM Implantable Cardioverter-Defibrillator
Table 1
LBT, Operating, and Wireless Frequencies Used by Different
Generations of SJM Implantable Cardioverter-Defibrillator
LBT,
kHz
Operating
Frequency,
kHz
Wireless Telemetry
(MICS Band),
MHz
SJM Promote (model RF-3213) 8 64 402–405
SJM Atlas II (model V-367) 8 64 N/A
SJM Atlas VR (model V-193) 8 8 N/A
Thoratec HMII PWM 7.2 — —M
BT listen-before-talking; MICSMedical Implant Communication Service; HMII Heartmate II;
WM  pulse-width modulator; SJM  St. Jude Medical.evices (LBT and operating frequency: 8 kHz), communication in
roximity of the Heartmate remained unavailable even if the initial
ecognition is performed far away from the LVAD pump. The
perating frequency of an ICD is thus not the only mechanism
hat explains the inability to interrogate the SJM ICDs in
roximity of the Heartmate II LVAD pump. Other potential
ources of interactions (such as the LBT frequency used) should be
aken into account before choosing a replacement device. In our
pinion, device interactions are important factors that should be
ecognized by manufacturers who are required to provide safety
nformation about this specific risk.
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eply
r. Le Poland de Waroux and colleagues have described an
nteraction of the Heartmate II left ventricular assist device
LVAD) (Thoratec Heartmate II, Thoratec, Pleasanton, Califor-
ia) and the St. Jude Medical (SJM) implantable cardioverter-
efibrillator (ICD) (Atlas II  HF, model V-367, St. Jude
edical, Sunnyvale, California) that is unique and not explained
y the previously published report from our group (1).
We commend Dr. Le Poland de Waroux and colleagues for
eciphering this new interaction; however, the nomenclature of the
nteraction is incorrect in their description. The interaction in
uestion is based upon the need for the device programmer to serve
oth older and newer generation devices.
The programmer (SJM-Merlin) utilizes an 8-kHz “test” pulse
f inductive telemetry (direct link to a programmer head) to
etermine whether a newer generation (64-kHz operating fre-
uency) or older generation (8-kHz operating frequency) is in
lace (A. Dianaty, written communication, May 2008). This test
r “handshake” pulse lasts 2 to 5 s, and it is the transient nature of
his pulse that explains the ability of shielding to overcome the
nteraction with the Atlas II (A. Dianaty, written communication,
ay 2008).
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December 2, 2008:1887–9While the 8-kHz inductive “handshake” is responsible for the
nteraction in question, it is not a function of the listen-before-
alking (LBT) protocol. The LBT protocol is a guideline issued by
he Federal Communication Commission to regulate utilization of
ireless telemetry devices in the Medical Implant Communications
ervice (MICS) band (2). The Federal Communication Commis-
ion mandates that all devices in the MICS band scan the
andwidth for current “traffic” before transmitting on this fre-
uency. All current ICD wireless telemetry must utilize LBT to
unction in the MICS band to minimize the potential for inter-
ctions. Boston Scientific devices operate in the Industrial, Scien-
ific, and Medical band and thus are not subject to the LBT
equirement (3).
The difficulties with device interactions will only become more
revalent over time as higher storage and more complex devices
ecessitate faster download speeds and more remote access op-
ions. As we encounter these complexities, it will take a collabo-
ative effort from physicians, engineers, and industry to navigate
hese problems. We thank Dr. Le Poland de Waroux and
olleagues for becoming an integral part of this collaboration.
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ffects of Inspiratory
uscle Training in Patients
ith Chronic Heart Failure
e read with interest the article by Chiappa et al. (1) reporting
n the improvement in limb blood flow and attenuation of
nspiratory muscle (IM) metaboreflex after inspiratory muscle
raining (IMT), explaining an IMT-induced increase in peakxygen consumption (VO2) and decrease in ventilatory equiva-
ent (VE/VCO2) in chronic heart failure patients with IM
eakness but not severely impaired functional capacity (2).
MT was performed using a threshold trainer at low intensity
30% of IM strength [PImax]).
A change in peak VO2 or VE/VCO2 was not shown before
sing a similar IMT methodology (3,4) even in more advanced
hronic heart failure with IM weakness (4). In contrast, peak
O2 was increased after high-intensity endurance respiratory
uscle training (5,6).
Although Dall’Ago et al. (2) reports that PImax is indepen-
ent of functional status, a low PImax was previously associated
ith reduced exercise capacity (7). The authors further report
1) that 4-week IMT resulted in diaphragmatic hypertrophy
nd PImax increase by 72%. However, in all IMT studies (3–6),
Imax increased by 25% to 28% within 8 to 12 weeks. Moreover,
hange in muscle morphology requires chronic training (8),
hile IMT using the threshold trainer did not change diaphrag-
atic contractility in normal subjects (9).
Thus, IM weakness might be overestimated in Ribeiro’s
tudies (1,2), although patients might have ‘felt better’ during
MT and increased their physical activity in parallel, possibly
ontributing to the reported benefits.
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